title: Predicted structures for kappa opioid G-protein coupled receptor bound to selective agonists.
abstract: Human kappa opioid receptor (κ-OR), a G protein-coupled receptor (GPCR), has been identified as a drug target for treatment of such human disorders as pain perception, neuroendocrine physiology, affective behavior, and cognition. In order to find more selective and active agonists, one would like to do structure based drug design. Indeed, there is an X-ray structure for an antagonist bound to κ-OR, but structures for activated GPCRs are quite different from those for the inactive GPCRs. Here we predict the ensemble of 24 low-energy structures of human kappa opioid receptor (κ-OR), obtained by application of the GEnSeMBLE (GPCR Ensemble of Structures in Membrane Bilayer Environment) complete sampling method, which evaluates 13 trillion combinations of tilt and rotation angles for κ-OR to select the best 24. To validate these structures, we used the DarwinDock complete sampling method to predict the binding sites for five known agonists (ethylketocyclazocine, bremazocine, pentazocine, nalorphine, and morphine) bound to all 24 κ-OR conformations. We find that some agonists bind selectively to receptor conformations that lack the salt bridge between transmembrane domains 3 and 6 as expected for active conformations. These 3D structures for κ-OR provide a structural basis for understanding ligand binding and activation of κ-OR, which should be useful for guiding subtype specific drug design.
authors: †Materials and Process Simulation Center (MC-139-74), California Institute of Technology, Pasadena, California 91125, United States.|‡College of Chemistry, Beijing Normal University, Beijing, 100875, People's Republic of China.
authors: Quanjie
authors: Q
authors: Li
authors: †Materials and Process Simulation Center (MC-139-74), California Institute of Technology, Pasadena, California 91125, United States.
authors: Soo-Kyung
authors: SK
authors: Kim
authors: †Materials and Process Simulation Center (MC-139-74), California Institute of Technology, Pasadena, California 91125, United States.
authors: William A
authors: WA
authors: Goddard
authors: ‡College of Chemistry, Beijing Normal University, Beijing, 100875, People's Republic of China.
authors: Guangju
authors: G
authors: Chen
authors: ‡College of Chemistry, Beijing Normal University, Beijing, 100875, People's Republic of China.
authors: Hongwei
authors: H
authors: Tan
mesh_terms: D001575:Benzomorphans / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D015195:Drug Design; D016314:Ethylketocyclazocine / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D062105:Molecular Docking Simulation; D009020:Morphine / Q000378:metabolism / Q000494:pharmacology; D009269:Nalorphine / Q000378:metabolism / Q000494:pharmacology; D010423:Pentazocine / Q000378:metabolism / Q000494:pharmacology; D011487:Protein Conformation; D043562:Receptors, G-Protein-Coupled / Q000737:chemistry; D017473:Receptors, Opioid, kappa / Q000819:agonists* / Q000737:chemistry* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D001575:Benzomorphans; D008024:Ligands; D043562:Receptors, G-Protein-Coupled; D017473:Receptors, Opioid, kappa; D016314:Ethylketocyclazocine; D009020:Morphine; C027248:bremazocine; D010423:Pentazocine; D009269:Nalorphine